Date
|
Headline
|
Type
|
| 2010-06-10 | HUMAN GENOME SCIENCES SUBMITS MARKETING APPLICATION FOR BENLYSTA | Press Release | |
| 2010-06-10 | PharmAthene - U.S. Government Accountability Office Denies Competitor Protest of SparVax Contract Modification | Press Release | |
| 2010-06-10 | HUMAN GENOME SCIENCES ANNOUNCES RESULTS OF RANDOMIZED PHASE 2 TRIAL OF MAPATUMUMAB IN MULTIPLE MYELOMA | Press Release | |
| 2010-05-19 | SCYNEXIS and Trevena Announce Strategic Collaboration to Enhance Discovery of Biased GPCR Ligands | Press Release | |
| 2010-05-10 | XANODYNE ANNOUNCES RENEWED FOCUS ON PAIN MANAGEMENT MARKET | Press Release | |
| 2010-04-29 | FDA Approves PROVENGE for Men with Advanced Prostate Cancer | Press Release | |
| 2010-04-27 | CARDIOVASCULAR SYSTEMS RECEIVES FDA APPROVAL FOR ORBIT II CORONARY CLINICAL TRIAL | Press Release | |
| 2010-04-22 | Verenium Awarded U.S. Department of Energy Funding for Demonstration-Scale Facility | Press Release | |
| 2010-04-22 | Verenium Announces Organizational Changes | Press Release | |
| 2010-04-19 | Sandoz to Acquire Oriel Therapeutics | Press release | |
| 2010-04-19 | GlobeImmune's Hepatitis C Product Candidate Improves End of Treatment Response | Press Release | |
| 2010-04-15 | GlobeImmune GI-5005 HCV Product Candidate Improves Virologic Response by 10 Percent | Press Release | |
| 2010-04-14 | Trevena Initiates Clinical Development of TRV120027 | Press release | |
| 2010-04-10 | XANODYNE AND FERRING ANNOUNCE CO-PROMOTE FOR ZIPSOR | Press Release | |
| 2010-04-01 | Verenium and BP Extend Galaxy Joint Development Program | Press Release | |
| 2010-03-17 | GlobeImmune Announces Presentations of GI-5005 Phase 2b Data | Press Release | |
| 2010-03-03 | World's Largest Soybean Plant to Use Verenium's Purifine | Press Release | |
| 2010-02-11 | Verenium Introduces New Enzyme at Upcoming RFA National Ethanol Conference | Press Release | |
| 2010-02-10 | Data on Anti-CD19 Compound, XmAb(r)5574, Published in Blood Journal | Article | |
| 2010-02-09 | Xencor Appoints Edgardo Baracchini, Ph.D., to Chief Business Officer | Press Release | |
| 2010-02-08 | Trevena Names David Soergel, M.D. Vice President and Head, Clinical Development | Press Release | |
| 2010-02-03 | Trevena Co-founder Honored with 2009 BBVA Foundation Frontiers of Knowledge Award | Press Release | |
| 2010-02-01 | Verenium and BP Extend Galaxy Joint Development Program | Press Release | |
| 2010-01-25 | Threshold Presents Clinical Trial Data of TH-302 at ASCO | Press Release | |
| 2010-01-19 | GlobeImmune Announces $17.5 Million Series E Financing | Press Release | |
| 2010-01-14 | Cardiovascular Systems Receives Conditional IDE Approval for ORBIT II Coronary Clinical Trial | Press Release | |
| 2010-01-11 | HUMAN GENOME SCIENCES REPORTS INCREASING MOMENTUM TOWARD COMMERCIALIZATION | Press Release | |
| 2010-01-07 | Tolerx Completes Enrollment in DEFEND-1, A Phase 3 Type 1 Diabetes Study With Otelixizumab | Press Release | |
| 2010-01-07 | Tolerx Completes Enrollment in DEFEND-1 Diabetes Study With Otelixizumab | Press Release | |
| 2010-01-05 | CardioVascular Systems Enrolls First Patient in COMPLIANCE 360° Clinical Trial | Press Release | |
| 2009-12-22 | Shire Submits Biologics License Application for REPLAGAL | Press Release | |
| 2009-12-16 | Xencor Receives Milestone Payment from Pfizer Under Antibody Technology License Agreement | Press Release | |
| 2009-12-16 | Xencor Receives Milestone Payment from Pfizer | Press Release | |
| 2009-12-16 | Antisoma - AS1411 shows activity in kidney cancer but AML remains priority | Press Release | |
| 2009-12-15 | HUMAN GENOME SCIENCES ANNOUNCES SUBMISSION OF MARKETING AUTHORIZATION FOR JOULFERON | Press Release | |
| 2009-12-11 | Dendreon Announces Exercise of Option by Underwriters | Press Release | |
| 2009-12-07 | Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board | Press Release | |
| 2009-11-30 | Xencor Licenses Antibody Optimization Technology | Press Release | |
| 2009-11-30 | Xencor Licenses Antibody Optimization Technology | Press Release | |
| 2009-11-24 | Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa | Press Release | |
| 2009-11-16 | Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV | Press Release | |
| 2009-11-12 | Shire Reports Analysis Emotional Lability in Children With ADHD Taking VYVANSE | Press Release | |
| 2009-11-09 | Verenium Reports Financial Results For The Third Quarter 2009 | Press Release | |
| 2009-11-06 | Threshold Pharmaceuticals Presents Interim Data From a Phase 1/2 Clinical Trial of TH-302 | Press Release | |
| 2009-11-05 | MiddleBrook Pharmaceuticals, Inc. Third Quarter 2009 ResultsConference Call Slides | Press Release | |
| 2009-11-05 | MiddleBrook Pharmaceuticals Reports Third Quarter 2009 Results | Press Release | |
| 2009-11-04 | Promedior Announces Publication of Preclinical Studies in Science Translational | Press Release | |
| 2009-11-04 | FDA Grants Priority Review for Shire’s velaglucerase alfa | Press Release | |
| 2009-11-03 | Trevena Awarded $7.65 Million NIH Grant | Press Release | |
| 2009-11-03 | Verenium and Syngenta Close Research Collaboration | Press Release | |
| 2009-11-02 | GlobeImmune's Hepatitis C Therapeutic Vaccine Combined with Standard of Care Increases End of Treatment Response Rate by 15% | Press Release | |
| 2009-11-02 | Dendreon Completes Submission of Biologics License Application for PROVENGE | Press Release | |
| 2009-10-30 | Shire Reports Tolerability and Clinical Effects Results of Daytrana | Press Release | |
| 2009-10-29 | XANODYNE RAISES $50 MILLION IN EQUITY FINANCING | Press Release | |
| 2009-10-23 | Louisville’s Potentia Pharmaceuticals sells drug to eye-care | Article | |
| 2009-10-23 | Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon | Press Release | |
| 2009-10-23 | SHIRE - INTUNIV 2009 Q&A | Press Release | |
| 2009-10-08 | Antisoma to amend ACCEDE phase III study of AS1413 | Press Release | |
| 2009-10-06 | GlobeImmune Announces Late-Breaker Presentation of GI-5005 Treatment Response Data at AASLD 2009 Meeting | Press Release | |
| 2009-10-06 | Threshold Pharmaceuticals Completes $35 Million Private Equity Financing | Press Release | |
| 2009-10-06 | Verenium Prices Public Offering of Common Stock and Warrants | Press Release | |
| 2009-10-05 | PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. | Press Release | |
| 2009-10-04 | Theraclone and Zenyaku Kogyo Announce Influenza Antibody Alliance | Press Release | |
| 2009-09-30 | Threshold Pharmaceuticals Announces Private Equity Financing of $35 Million | Press Release | |
| 2009-09-24 | GENVEC RECEIVES FOURTH-YEAR FUNDING FROM NIAID FOR HIV VACCINE CONTRACT | Press Release | |
| 2009-09-24 | Dendreon Reports PROVENGE Progress and Future Pipeline Plans | Press Release | |
| 2009-09-22 | CSI Reports Two-Year Data Showing Durable Outcomes in Patients Treated with Diamondback 360° PAD System | Press Release | |
| 2009-09-21 | Threshold Pharmaceuticals Provides Clinical Trial Update From a Complete Phase 1/2 | Press Release | |
| 2009-09-14 | Antisoma’s preliminary results for the year ended 30 June 2009 | Press Release | |
| 2009-09-10 | Ascent Therapeutics Achieves Preclinical in vivo Proof-of-principle with Novel Pepducin™ | Press Release | |
| 2009-09-09 | Seahorse Bioscience to Present Novel Cellular Bioenergetics Data | Press Release | |
| 2009-09-03 | Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic Factive(R) | Press Release | |
| 2009-09-03 | PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation | Press Release | |
| 2009-09-03 | Two New Antibodies Found to Cripple HIV Findings Reveal an Achilles Heel on the Virus for AIDS Vaccine Researchers to Exploit | Article | |
| 2009-09-03 | Shire Announces FDA Approval of Once-Daily INTUNIV | Press Release | |
| 2009-09-02 | Bayer Acquires Two Prescription Dermatology Product Lines from SkinMedica in the U.S. | Press Release | |
| 2009-09-01 | MiddleBrook Pharmaceuticals Announces Sales Force Realignment, Cost-Saving Measures | Press Release | |
| 2009-08-28 | Verenium Completes 5.5% Convertible Notes Exchange | Press Release | |
| 2009-08-27 | GENVEC ANNOUNCES REGISTERED OFFERING OF $6 MILLION IN COMMON STOCK AND WARRANTS | Press Release | |
| 2009-08-25 | GENVEC RECEIVES AN APPROXIMATELY $2.5 MILLION GRANT TO SUPPORT NOVEL CELL LINE DEVELOPMENT | Press Release | |
| 2009-08-17 | PharmAthene Strengthens Senior Management Team; Appoints Charles A. Reinhart III | Press Release | |
| 2009-08-13 | PharmAthene Reports Second Quarter 2009 Financial and Operational Results | Press Release | |
| 2009-08-11 | Antisoma and Bryan Oncor announce deal for anti-cancer drug P2045 | Press Release | |
| 2009-08-11 | Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results | Press Release | |
| 2009-08-11 | Tolerx Announces Amendment to Phase 3 DEFEND Protocol | Press Release | |
| 2009-08-10 | Verenium Reports Financial Results for the Second Quarter 2009 | Press Release | |
| 2009-08-06 | GENVEC REPORTS SECOND QUARTER 2009 FINANCIAL RESULTS | Press Release | |
| 2009-08-06 | MiddleBrook Pharmaceuticals Reports Second Quarter 2009 Results | Press Release | |
| 2009-08-06 | Threshold Pharmaceuticals Reports Second Quarter 2009 Financial Results | Press Release | |
| 2009-08-05 | Radius’ Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) | Press Release | |
| 2009-08-04 | Results From TH-302 Clinical Trials Presented at International Lung Cancer Meeting | Press Release | |
| 2009-08-03 | Shire Reports Positive Results from First of Three Phase III Trials of velaglucerase alfa | Press Release | |
| 2009-07-30 | Cornerstone Therapeutics Announces Closing of Chiesi Transaction | Press Release | |
| 2009-07-30 | Cornerstone Therapeutics Joins the Russell 3000J Index | Press Release | |
| 2009-07-29 | BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol | Press Release | |
| 2009-07-27 | GENVEC EXPANDS CONTRACT SUPPORTING MALARIA VACCINE PROGRAM | Press Release | |
| 2009-07-23 | Promedior Initiates Phase 1 Clinical Trial of PRM-151, | Press Release | |
| 2009-07-21 | FoldRx Pharmaceuticals Announces Positive Results from Pivotal Phase II/III Clinica | Press Release | |
| 2009-07-20 | HUMAN GENOME SCIENCES AND GLAXOSMITHKLINE ANNOUNCE POSITIVE PHASE 3 RESULTS FOR BENLYSTA | Press Release | |
| 2009-07-15 | Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product | Press Release | |
| 2009-07-15 | MiddleBrook Pharmaceuticals Announces $20 Maximum Copay Program for MOXATAG(R) | Press Release | |
| 2009-07-13 | Cornerstone Therapeutics Signs Definitive Asset Purchase Agreement to Acquire Commercial Rights to | Press Release | |
| 2009-07-09 | PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA | Press Release | |
| 2009-07-09 | HUMAN GENOME SCIENCES-NEJM SUPPORTS USE OF ABTHRAX | Press Release | |
| 2009-07-08 | Antisoma announces discontinuation of development of AS1402 | Press Release | |
| 2009-07-07 | CATALYST BIOSCIENCES ANNOUNCES AGREEMENT WITH MEDIMMUNE TO DISCOVER AND | Press Release | |
| 2009-07-07 | U.S. Food and Drug Administration and Xanodyne Agree on a Plan to Keep Propoxyphe Products available | Press Release | |
| 2009-07-06 | IAVI and Theraclone Expand HIV Antibody Discovery Collaboration | Press Release | |
| 2009-07-06 | Verenium Completes Amendment to 8% Senior Convertible Notes | Press Release | |
| 2009-07-01 | MiddleBrook Pharmaceuticals Secures $10 Million Revolving Line of Credit | Press Release | |
| 2009-06-30 | CATALYST BIOSCIENCES AND WYETH PHARMACEUTICALS ANNOUNCE WORLDWIDE | Press Release | |
| 2009-06-29 | GENVEC RECEIVES GRANT FOR MALARIA VACCINE PROGRAM | Press Release | |
| 2009-06-29 | FierceBiotech Names VaxInnate as One of the “Fierce 15" Biotech Companies of 2009 | Press Release | |
| 2009-06-25 | Verenium and BP Invited to Begin Negotiations for Next Phase of U.S. Department of Energy Loan Guarantee Program | Press Release | |
| 2009-06-22 | Verenium and Add Food Service GmbH Announce Commercial Distribution Partnership for Fuelzyme® and Veretase™ Enzymes | Press Release | |
| 2009-06-19 | HUMAN GENOME SCIENCES ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2B TRIAL OF ALBUFERON | Press Release | |
| 2009-06-17 | VaxInnate Reports Positive Results from Preclinical Testing of Swine Flu Vaccine Developed Using Novel Technology | Press Release | |
| 2009-06-11 | HUMAN GENOME SCIENCES REPORTS POSITIVE DATA FOR BENLYSTA | | |
| 2009-06-08 | Tolerx Presents Data at 69TH Scientific Sessions of The American Diabetes Association | Press Release | |
| 2009-06-08 | FYI FROM HUMAN GENOME SCIENCES: GLAXOSMITHKLINE STUDY ON SYNCRIA® | Press Release | |
| 2009-06-04 | Xanodyne Announces New President/CEO and Completes $38 million equity financing | Press Release | |
| 2009-06-02 | Ascent Therapeutics Appoints Industry Leaders to Senior Management | Press Release | |
| 2009-06-01 | TNFERADE™ PHASE III DATA PRESENTED AT ASCO | Press Release | |
| 2009-05-31 | Antisoma’s AS1409 shows anti-cancer activity in phase I trial | Press Release | |
| 2009-05-29 | Antisoma to advance AS1411 in AML based on positive phase II data presented at ASCO | Press Release | |
| 2009-05-29 | New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience | Press Release | |
| 2009-05-21 | Antisoma - Phase II trial of ASA404 published in Lung Cancer | Press Release | |
| 2009-05-15 | GlobeImmune and Celgene Corporation Announce Strategic Global Oncology Alliance | Press Release | |
| 2009-05-12 | Antisoma sells oral fludarabine to sanofi-aventis U.S. for USD 65 million | Press Release | |
| 2009-05-07 | Antisoma Interim Management Statement | Press Release | |
| 2009-05-07 | Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmaceutici SpA | Press Release | |
| 2009-05-07 | Cornerstone Therapeutics Reports First Quarter 2009 Financial Results | Press Release | |
| 2009-05-04 | Potentia Pharmaceuticals' POT-4 Drug Candidate for Age-Related Macular Degeneration | Press Release | |
| 2009-05-01 | MiddleBrook Pharmaceuticals Launches MOXATAG(TM) Website, Announces Early Prescription Data for MOXATAG | Press Release | |
| 2009-04-28 | Dendreon Presents Data at AUA Demonstrate PROVENGE Significantly Prolongs Survival | Press Release | |
| 2009-04-24 | CATALYST BIOSCIENCES EXPANDS SCIENTIFIC ADVISORY BOARD WITH LEADING EXPERTS IN | Press Release | |
| 2009-04-23 | FATE THERAPEUTICS AND STEMGENT LAUNCH CATALYST | Press Release | |
| 2009-04-23 | GlobeImmune's Hepatitis C Therapeutic Vaccine, GI-5005, Improves EVR | Press Release | |
| 2009-04-21 | Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer | Press Release | |
| 2009-04-20 | Data on three Antisoma drugs presented at AACR meeting | Press Release | |
| 2009-04-19 | Dendreon Announces Data on PROVENGE | Press Release | |
| 2009-04-16 | GlobeImmune Initiates Phase 1 Clinical Trial with NCI | Press Release | |
| 2009-04-13 | Verenium Launches High Performance Enzyme for Food and Beverage Applications | Press Release | |
| 2009-04-13 | Local companies delve deep into cell origami | Article | |
| 2009-04-07 | Antibodies for HIV, Long Dismissed, Show Signs of Comeback at Seattle’s Theraclone | Article | |
| 2009-04-03 | Verenium Announces Organizational Changes | Press Release | |
| 2009-03-30 | Spaltudaq Corp. Announces Identification of Broadly and Potently Neutralizing Human HIV Antibodies and Name Change to Theraclone Sciences, Inc. | Press Release | |
| 2009-03-26 | Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results | Press Release | |
| 2009-03-25 | Antisoma - Phase III development of ASA404 in lung cancer extended to Japan | Press Release | |
| 2009-03-24 | Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes | Press Release | |
| 2009-03-24 | Verenium and Alfa Laval Announce Collaboration on Purifine PLC Enzyme | Press Release | |
| 2009-03-23 | Xencor Licenses XTEND (tm) Antibody Half-Life Prolongation Platform to Merck & Co., Inc. | Press Release | |
| 2009-03-09 | TetraLogic Pharmaceuticals Licenses Exclusive Rights to Novel Necrosis Inhibitors from Harvard Medical School | Press Release | |
| 2009-03-09 | TETRALOGIC PHARMACEUTICALS LICENSES EXCLUSIVE RIGHTS TO NOVEL NECROSIS INHIBITORS FROM HARVARD | Press Release | |
| 2009-03-02 | Xencor and Pfizer Enter into Antibody Technology Licensing Agreement | Press Release | |
| 2009-02-23 | Xencor and CSL Limited Establish Antibody Optimization Collaboration | Press Release | |
| 2009-02-19 | Shire delivers excellent growth for the year | Press Release | |
| 2009-02-18 | BP and Verenium Form Leading Cellulosic Ethanol Venture to Deliver Advanced Biofuels | Press Release | |
| 2009-02-16 | Antisoma reports half-year results | Press Release | |
| 2009-02-12 | Antisoma - ASA404 to be developed in breast cancer | Press Release | |
| 2009-02-09 | Sequoia Pharmaceuticals presents proof of clinical concept of SPI-452, a | Press Release | |
| 2009-02-09 | Ligand Enters into Screening Agreement with Trevena | Press Release | |
| 2009-01-30 | Ligand Enters into Screening Agreement with Trevena | Press Release | |
| 2009-01-13 | Antisoma - ASA404 enters pivotal phase III trial in second-line lung cancer | Press Release | |
| 2009-01-09 | Antisoma - Phase III trial of ASA404 in lung cancer completes patient enrolment | Press Release | |
